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Abstract
Nearly 21 million components of blood and whole blood and transfused annually in the
United States, while on average only 13.6 million units of blood are donated. As the demand
for Red Blood Cells (RBCs) continues to increase due to the aging population, this deficit
will be more significant. Despite decades of research to develop hemoglobin (Hb) based
oxygen (O2) carriers (HBOCs) as RBC substitutes, there are no products approved for clini-
cal use. Lumbricus terrestris erythrocruorin (LtEc) is the large acellular O2 carrying protein
complex found in the earthworm Lumbricus terrestris. LtEc is an extremely stable protein
complex, resistant to autoxidation, and capable of transporting O2 to tissue when transfused
into mammals. These characteristics render LtEc a promising candidate for the develop-
ment of the next generation HBOCs. LtEc has a short half-life in circulation, limiting its appli-
cation as a bridge over days, until blood became available. Conjugation with polyethylene
glycol (PEG-LtEc) can extend LtEc circulation time. This study explores PEG-LtEc pharma-
cokinetics and pharmacodynamics. To study PEG-LtEc pharmacokinetics, hamsters instru-
mented with the dorsal window chamber were subjected to a 40% exchange transfusion
with 10 g/dL PEG-LtEc or LtEc and followed for 48 hours. To study the vascular response of
PEG-LtEc, hamsters instrumented with the dorsal window chamber received multiple infu-
sions of 10 g/dL PEG-LtEc or LtEc solution to increase plasma LtEc concentration to 0.5,
then 1.0, and 1.5 g/dL, while monitoring the animals’ systemic and microcirculatory parame-
ters. Results confirm that PEGylation of LtEc increases its circulation time, extending the
half-life to 70 hours, 4 times longer than that of unPEGylated LtEc. However, PEGylation
increased the rate of LtEc oxidation in vivo. Vascular analysis verified that PEG-LtEc
showed the absence of microvascular vasoconstriction or systemic hypertension. The
molecular size of PEG-LtEc did not change the colloid osmotic pressure or blood volume
expansion capacity compared to LtEc, due to LtEc’s already large molecular size. Taken
together, these results further encourage the development of PEG-LtEc as an O2 carrying
therapeutic.
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Introduction
Both in the United States (US) and globally, the need for red blood cell (RBC) transfusions has
steadily increased over the years.[1] Studies indicate that the demand for RBCs in the US rela-
tive to the amount collected will create a shortage of 3 million units of RBCs by the year 2030.
[1] This shortage of RBCs is highest in sub-Saharan Africa, where the demand for RBCs is dou-
ble the amount of RBCs collected from donors.[2] According to the World Health Organiza-
tion (WHO), 20% of deaths due to malaria and 40% of deaths during childbirth in third-world
countries are related to an inadequate blood supply.[3] Since sophisticated blood screening tech-
niques are available in the US, disease transmission after transfusion is rare; however, according
to WHO, in some third world countries, including those in Africa, there is a 95–100% chance of
human immunodeficiency virus (HIV) contraction after transfusion of unmonitored and unsafe
allogeneic blood.[4] Even in the US, the chance of bacterial contamination through RBC transfu-
sion is still high (1 in 38,500).[5, 6] It has also been reported that transfusion of RBCs may increase
the risk of transmission of hepatitis, variant Creutzfeldt-Jakob disease, West Nile virus, Zika virus,
and internal systemic complications such as immune system suppression, acute lung injury, and
allergic reactions. Additionally, RBC accessibility during emergency scenarios and on the battle-
field, is extremely limited due to the short shelf-life, and required storage conditions for RBCs. In
these conditions, 25% of all trauma casualties are transfused with an average of 1–4 units of RBCs.
[7] At least 80% of casualties, who could potentially survive, die from an inadequate supply of
RBCs and exsanguinating hemorrhage.[8] The growing demand for RBCs along with the afore-
mentioned issues associated with RBC transfusion justify the need for alternatives to RBCs, that
have greater availability, accessibility, shelf life, oxygen (O2) transport capacity, and safety.
Over the last few decades, artificial O2 carriers such as perfluorocarbon (PFC) emulsions
and hemoglobin (Hb) based O2 carriers (HBOCs) have been developed as potential RBC sub-
stitutes.[9] PFCs and HBOCs have reached clinical trials; however, short circulation time and
adverse side-effects, including stroke, multi-organ failure, myocardial infarction, acute respira-
tory distress syndrome, and even death, have resulted in termination of further development.
[10] The chemical modifications of Hb necessary to synthesize HBOCs generally increase the
autoxidation rate of Hb and consequently oxidative tissue injury.[11] Some of the adverse
side-effects previously observed with HBOCs have been attributed to Hb autoxidation, extrav-
asation through the blood vessel wall, nitric oxide (NO) scavenging, and hyper-oxygenation of
the vessel wall (i.e. O2 autoregulation).[9] Vasoconstriction is perceived to be the most critical
barrier hampering the development of HBOCs. HBOC-induced vasoconstriction has been
attributed to NO scavenging by acellular Hb via either NO binding to deoxyHb, resulting in
the highly stable ferrous nitrosyl Hb derivative, or through the NO dioxygenase reaction
between NO and oxygenated Hb (oxyHb) to yield methemoglobin (metHb) and nitrate.
Lumbricus Terrestris erythrocruorin (LtEc) has naturally adapted to limit the problems
associated with acellular HBOCs [12]. Hirsch et al. previously have shown that LtEc when
injected into mice and rats produced no noticeable side effects [12]. LtEc has been studied
before as an O2 carrier because it has a lower rate of oxidation [redox potential, Eo = 112 mV]
compared to mammalian Hbs [Eo = -50 mV for HbA] [13]. Additionally, LtEc and other ery-
throcruorins have an extremely low rate of NO scavenging [14]. LtEc is a complex structure,
containing 144 globin subunits and 36 linker proteins. The complex consists of five types of
globins [A, B, C, and D1 or D2] and four types of linkers [14]. Each globin contains a heme
group and binds O2. Each subunit assembles into an ABC trimer via intermolecular disulfide
bonds. The trimers pairs with D monomers to form the ABCD tetramers through electrostatic
and hydrophobic interactions, which then associate with two more tetramers via linkers to
form dodecamers. Finally, twelve dodecamers assemble into the hexagonal bilayer structure,
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which has a MW of 3.6 MDa and a molecular radius of approximately 15 nm. As LtEc is a rela-
tively large and stable molecule, it is difficult to purify; however, to overcome this limitation,
LtEc can been purified by tangential-flow filtration (TFF). In addition to TFF being scalable, is
a reliable process with high yield (grams from 1k worms) and with relatively low costs [14].
Recently, we have shown that Lumbricus Terrestris erythrocruorin (LtEc) can be used as a
HBOC in small animals.[14, 15] LtEc has been shown to have a circulation time of 13–17
hours in vivo. Transfused RBCs remain in circulation and continue to function for several days
and even up to weeks; the same, however, cannot be said about HBOCs. It is therefore a signifi-
cant challenge to formulate HBOCs that match the efficacy and functionality of RBCs. An opti-
mal HBOC should have a persistent circulation time coupled with a long-functional half-life to
transport and deliver O2, in order to reduce the frequency of administration of the HBOC
until either blood for transfusion is available or erythropoiesis replenishes the circulating
RBCs. LtEc’s short circulation time is a serious limitation in its use as an O2 ‘bridge’ during
anemia. This study evaluates a strategy to increase LtEc circulation time based on polyethylene
glycol (PEG) surface conjugation to purified LtEc. PEGylation is a common method used to
decrease excretion, extend circulation time, and limit immune recognition of proteins in the
circulation.[16] This study aims to the test whether PEGylated LtEc (PEG-LtEc) increases circu-
lation half-life, while maintaining LtEc favorable properties and preserving reduced vasoactivity.
The pharmacokinetics of PEG-LtEc was studied for 48 hours after an exchange transfusion of
40% of the animal’s blood volume (BV) with 10 g/dL PEG-LtEc solution. The vascular response
of PEG-LtEc was studied via infusion of a 10 g/dL PEG-LtEc solution to increase consecutively
PEG-LtEc plasma concentration to 0.5, then 1.0, and lastly 1.5 g/dL, while monitoring the ani-
mals’ systemic and microcirculatory parameters. UnPEGylated LtEc was used as a control.
Vasoactivity of LtEc and PEG-LtEc was assessed in the blood vessels most sensitive to the well
accepted mechanism of vasoactivity by HBOCs (NO scavenging by heme, O2 over supply by
acellular Hb, and Hb extravasation). These microvascular blood vessels have diameters below
80 micrometers, and their tunica media is made up mostly of smooth muscle fibers arranged
around the vessel to maximally regulate blood flow in the microcirculation. The larger arteries,
however, do not actively change diameter, as changes in these arteries would likely result in
drastic changes in blood flow downstream. Our results demonstrate that PEG-LtEc circulated
four times longer that of LtEc with no observable vasoconstriction and hypertension, while pre-
serving microvascular blood flow and functional capillary density (FCD).
Material and Methods
Earthworm Preparation
For each round of LtEc purification, 1,000 Canadian nightcrawlers (Lumbricus terrestris) were
purchased from Wholesale Bait Company (Hamilton, OH). Worms were rinsed in tap water to
remove dirt, and 1 L batches of worms were extensively washed with 20–30 L of tap water to
remove as much mucus as possible. A blender was used to homogenize the worms (puree mode
for ~10 seconds) and the homogenate was immediately centrifuged at 3,716 g for 40 minutes at
4˚C. Solid debris was discarded and the cloudy red supernatant was centrifuged at 18,000 g for
20 minutes at 10–15˚C. The clear red supernatant (~2.0 L per 1,000 worms) was then filtered
through to remove any remaining large particles.
Purification of LtEc
The earthworm homogenate was passed through two 0.22 μm tangential flow filtration (TFF)
cartridges in parallel (1050 cm2 surface area, Spectrum Labs, Rancho Dominguez, CA) at 450
mL/min until most the sample volume was transmitted through the membrane. The 0.22 μm
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filtrate (1.8–2.0 L) was then concentrated on two 500 kDa TFF cartridges (1050 cm2 surface
area, Spectrum Labs) at 450 mL/min down to a final volume of approximately 200 mL. The
500 kDa retentate was then diafiltered by diluting it to 2 L with buffer and then concentrating
it down to 200 mL ten times. The retentate was first diluted with 20 mM Tris buffer (pH 7.0)
during the first eight rounds of diafiltration and a modified lactated Ringer’s buffer (115 mM
NaCl, 4 mM KCl, 1.4 mM CaCl2, 13 mM NaOH, 12.25 mM N-acetylcysteine, 0.3% sodium lac-
tate, pH 7.0) during the last two rounds of diafiltration. During the final round of diafiltration,
the retentate was concentrated to 20–50 mL and sterilized by passing it through a 0.45 μm
syringe filter. The purified Ec was then stored at -80˚C until needed. After each round of puri-
fication, all filters were rinsed and soaked in 0.2 M NaOH for 1 hour, then rinsed with distilled
water and stored at 4˚C.[15]
PEGylation of LtEc
LtEc (75 mg/ml) was incubated with 5 mM 2-iminothiolane and 10 mM maleimide-PEG-5000
in PBS, pH 7.4 at 4˚C overnight. After incubation, excess (unreacted) reagents were removed
by filtering the reaction mixture through 50 kDa membrane filters (Millipore) by repeated
dilution/centrifugation. The removal of the PEG reagent was monitored by size exclusion
chromatography of the reaction mixture using a refractive Index detector.[17] The final prod-
uct of PEGylated LtEc (PEG-LtEc) was concentrated to 100 mg/ml for animal studies.
Viscosity and Colloid Osmotic Pressure
Viscosity was measured at a shear rate of 160/sec (Brookfield Engineering Laboratories, Mid-
dleboro, MA). Colloid osmotic pressure (COP) was measured using a 4420 Colloid Osmome-
ter (Wescor, Logan, UT).
Mass Spectral Analysis
Samples were prepared for Matrix Assisted Laser Desorption Ionization (MALDI) by diluting
LtEc and PEG-LtEc to 1 mg/mL, then mixing them in a 1:1:1 ratio with 1M HCl and a matrix
solution of 50% v/v acetonitrile saturated with sinapic acid [18]. Cytochrome C (12,361 g/mol),
apomyoglobin (16,952 g/mol), and human serum albumin (66,437 g/mol) were used as molecu-
lar weight (MW) standards on a Bruker FLEX MALDI-TOF (Bruker Daltonics, Billerica, MA)
and analyzed in the linear mode [18].
Oxygen equilibrium Curve (OEC)
OECs were collected using the TCS Hemox Analyze (TCS Scientific Company, New Hope,
PA). Briefly, approximately 20–200 μL of Hb sample (final concentration ~5 mg/mL) was
diluted with 4.9 mL of Hemox Buffer (pH 7.4). 20μL of Additive A (albumin), 10 μL of Addi-
tive B, and 10 μL of an anti-foaming agent (TCS Scientific) were added to the solution. During
deoxygenation the O2 tension and %O2 saturation are recorded to obtain an OEC, and P50
value (partial pressure of O2 at which Hb is 50% saturated with O2). The Hemox analyzer soft-
ware was used to calculate P50 and cooperativity based on O2 binding.
Nitrite Reductase
Nitrite reductase reactions were performed in parallel (HbA, LtHb and PEG-LtEc) using the
argon-purged deoxy heme at 0.20 mM in the presence of 1 mM dithionite. Changes in the
deoxy heme Soret 430 nm band were recorded as a function of time (Lambda 20 UV/VIS
spectrometer; Perkin Elmer, Foster City, CA). Under these conditions, the nitrite reductase
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reaction is modified, since the metHb generated from the reaction is reduced back to deoxyHb
by the excess dithionite. The deoxy-Hb binds NO, yielding the ferrous NO derivative of Hb
(NOHb). This approach is based on the relatively large extinction coefficient for deoxy heme
(@ 430nm), as compared to the smaller extinction coefficients of both NOHb and metHb. The
initial linear portion of the curve was used to calculate the initial reaction rates.
Animal Preparation
In vivo studies were performed in 54–66 g male Golden Syrian Hamsters (Charles River Labo-
ratories, Boston, MA) fitted with a dorsal skinfold window chamber. The hamster window
chamber model is widely used for microvascular studies in the unanesthetized state (complete
surgical technique is described in the literature).[19, 20] Arterial and venous catheters filled
with a heparinized saline solution (30 IU/ml) were implanted into the carotid and jugular ves-
sels. Catheters were tunneled under the skin, exteriorized at the dorsal side of the neck, and
securely attached to the window frame. Animal handling and care followed the NIH Guide for
the Care and Use of Laboratory Animals. The experimental protocol was approved by UC San
Diego Animal Care and Use Committee (IACUC).
Inclusion Criteria
Animals were considered suitable for experiments if systemic parameters were within normal
range, namely, heart rate (HR) > 340 beats/min, mean arterial blood pressure (MAP) > 80
mmHg, systemic Hct > 45%, and arterial O2 partial pressure (PaO2)> 50 mmHg. Addition-
ally, animals were examined 3 to 4 days after implantation surgery, their tissue was observed
under 650× magnification, and only animals without signs of low perfusion, inflammation,
edema or bleeding were included in the study.
Systemic Parameters
MAP and HR were recorded continuously (MP 150, Biopac System, Santa Barbara, CA). Hct
levels were measured from centrifuged arterial blood samples taken in heparinized capillary
tubes. Hb content was determined spectrophotometrically (B-Hemoglobin, Hemocue).
Blood Chemistry and Biophysical Properties
Arterial blood was collected in heparinized glass capillaries (50 μL) and immediately analyzed
for pO2, pCO2, base excess, and pH (Rapidlab 248, Bayer, Norwood, MA).
Estimation of Yield and MetHb Level
LtEc concentration and the percent of oxidized LtEc and PEG-LtEc (i.e. met-LtEc and met-
PEG-LtEc) were measured using the cyanomethemoglobin method.[21]
Volume Expansion
Changes in blood volume was calculated as the difference in Hct before infusion (Hct0) and
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Experimental Groups
Experimental groups were labeled based on the test solution infused and included LtEc and
PEG-LtEc test solutions.
Pharmacokinetics—Exchange Transfusion Protocol
Pharmacokinetics was studied for 48 hours after exchange transfusion with 10 g/dL PEG-LtEc
or LtEc solution. Briefly, hamsters fitted with the dorsal window chamber were exchanged
with 40% of the estimated BV (7% of body weight). Test solutions were infused into the jugular
vein catheter at a rate of 100 μl/min with simultaneous blood withdrawal at the same rate from
the carotid artery catheter via a dual syringe pump (Harvard Apparatus, Holliston, MA).
Blood samples (50 μL) were taken after exchange transfusion at 0.5, 1, 2, 4, 8, 12, 24, and 48
hours. PEG-LtEc and LtEc pharmacokinetic parameters were determined using non-compart-
mental analysis.
Vascular Responses—Hypervolemic Infusion (Top-Load) Protocol
PEG-LtEc and LtEc vascular responses were studied after infusion of 10 g/dL PEG-LtEc or
LtEc solution to increase protein plasma concentration. Hamsters fitted with the dorsal win-
dow chamber were randomly divided into two experimental groups. Three consecutive infusions
of the test solutions were administered to increase the plasma protein concentrations to 0.5, 1.0,
and ultimately 1.5 g/dL. All infusions were performed intravenously at a rate of 100 μL/min. The
plasma Hb concentration was determined spectrophotometrically (B-hemoglobin, Hemocue,
Stockholm, Sweden). Infusion volumes of each test solution required to increase the plasma pro-
tein concentration by 0.5 g/dL were estimated in each animal before infusion, based on the esti-
mated animal BV and Hct, as 0.05 × (1 −Hct) × BV. Five minutes after infusion, the plasma
protein concentration was verified and increased if necessary. After each infusion, animals were
allowed 30 to 40 minutes to stabilize before systemic and microvascular characterization.
Microvascular Experimental Setup
The unanesthetized animal was placed in a restraining tube with a longitudinal slit from which
the window chamber protruded and was then fixed to the microscopic stage for transillumina-
tion with a customized intravital microscope (BX51WI, Olympus, New Hyde Park, NY). Ani-
mals were given 20 minutes to adjust to the tube environment before any measurements were
made. The tissue image was projected onto a charge-coupled device camera (4815, COHU,
San Diego, CA) connected to a video recorder and viewed on a monitor. Measurements were
carried out using a 40× (LUMPFL-WIR, numerical aperture 0.8, Olympus) water immersion
objective.
Functional Capillary Density
Functional capillaries (defined as those capillary segments that exhibit RBC transit of at least a
single RBC in a 45-second period in 10 successive microscopic fields) were assessed in a region
measuring 0.46 mm2. The relative change in functional capillary density (FCD) from baseline
levels after each infusion is indicative of the extent of capillary perfusion.[22]
Microhemodynamics
Arteriolar and venular blood flow velocities were measured online by using the photodiode
cross-correlation method (Vista Electronics, San Diego, CA).[23] The measured centerline
velocity (V) was corrected according to blood vessel size to obtain the mean RBC velocity
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(V/Rv), where Rv represents the ratio between the blood vessel centerline V and the blood ves-
sel mean blood V based on data obtained in glass tubes. According to Lipowsky and Zweifach,
Rv = 1.6 for blood vessels between 15 and 90 μm diameter, but not for larger blood vessels.[24]
A video image-shearing method was used to measure blood vessel diameter D (Vista Electron-










Results are presented as the mean ± standard deviation. Data within each group were analyzed
using analysis of variance for repeated measurements (ANOVA, Kruskal-Wallis test). When
appropriate, post hoc analyses were performed with the Dunn’s multiple comparison test.
Comparison between samples was performed using two-way ANOVA (Hb plasma concentra-
tion); post hoc analyses were performed with Bonferroni posttests. Microhemodynamic data
are presented as absolute values and ratios relative to baseline values. A ratio of 1.0 signifies no
change from baseline, while lower and higher ratios are indicative of changes proportionally
lower and higher than baseline (i.e., 1.5 represents a 50% increase from the baseline level). The
same blood vessels and capillary fields were monitored throughout the study, such that direct
comparisons to their baseline levels could be performed, allowing for more reliable statistics
on small sample populations. All statistics were calculated using computer software (GraphPad
Prism 6, GraphPad Software, Inc., San Diego, CA). Changes were considered significant if p
values were less than 0.05.
Results
Oxygen Binding and Biophysical Properties
Summary of O2 binding and biophysical characteristics are summarized in Table 1. PEGyla-
tion of LtEc had no statistically significant effect on O2 affinity, (P50, O2 tension at which Hb
is 50% saturated with O2). However, PEGylation statistically decreased cooperativity of LtEc,
suggesting that PEG reduces subunit conformational switch from a weak to strong O2 binding
state and limits the interactions between subunits. PEGylation also resulted in statistically sig-
nificant increases in both viscosity and colloid oncotic pressure (COP) relative to LtEC.
Mass Distribution
The MALDI mass spectrum of LtEc and PEG-LtEc (Fig 1A) show similar to LtEc mass spectra
existing in the literature [18]. For LtEc, monometers and linkers appear near their expected
Table 1. Properties of LtEc and PEG-LtEc.
Properties LtEc PEG-LtEc
P50, mmHg 26.0 ± 1.2 25.2 ± 1.4
Cooperativity 2.4 ± 0.3 1.9 ± 0.2†
MetHb, % 4.6 ± 1.8 4.1 ± 1.6
COP, mmHg 1.0 ± 0.2 3.8 ± 0.3†
Viscosity, cP 1.3 ± 0.1 1.9 ± 0.1
Results obtained from three (3) different batches of purification and PEGylation.
†, P<0.05 compared to LtEc
doi:10.1371/journal.pone.0170041.t001
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MW (16 kDa and 24–32 kDa), respectively. While trimers appear to have a MW of around 50
kDa and tetramers a MW near 70 kDa. PEGylation affects the molecular weights of the sub-
units, as it shifts the MW by 5 and 10 kDa for monomers and trimers and tetramers, respec-
tively. However, the native mass spectrum signature of the unPEGylated subunits remains in
the mass spectrum of PEG-LtEc, suggesting that only a fraction of the subunits was PEGylated
and another fraction remains unPEGylated. Additionally, it is important to note, that no
major impurities were detected in the MALDI mass spectrum.
Nitrite Reductase
Nitrite reductase at various nitrite to heme ratios for HbA, LtEc and PEG-LtEc are shown in
Fig 1B. The normalized nitrite-induced decay of the deoxyheme population as a function of
the ratio of nitrite to heme for LtEc and PEG-LtEc appears to exhibit two distinct phases,
whereas HbA only exhibits one phase. LtHb does not undergo any R/T allosteric transitions;
hence the two distinct phases for LtHb and PEG-LtEc can be attributed to the fact that there
are two different heme populations. The first phase and fast nitrite reductase rates at a 1:1
nitrite to heme ratio were 0.142, 0.068 and 0.076 μM/s for HbA, LtEc and PEG-LtEc respec-
tively. The initial fast nitrite reductase rate increased for HbA with the nitrite to heme ratios.
However, for LtEc and PEG-LtEc, the initial fast nitrite reductase rate remained constant and
the second slower nitrite reductase rate phase decreased with higher ratios of nitrite to heme.
Fig 1. A. MALDI mass spectrum. a) LtEc (top) and b) PEG-LtEc (botton), MW range of 10–80 kDa. I) monomers; II) linkers; III) trimers (A, B, and
C subunits); IV) tetramers (A, B, C, and D subunits). B. Nitrite reductase at pH 7.0 monitored as the decay of the 430 nm Soret band as a
function of the ratio nitrite to heme. a) 1:1; b) 2:1; c) 5:1. Heme concentration in all cases was 0.20 mM. The lines represent fits to the data. The
traces were all normalized for comparison of protein kinetics.
doi:10.1371/journal.pone.0170041.g001
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Pharmacokinetics of LtEc and PEG-LtEc
Pharmacokinetics results are summarized in Table 2. The mean residence time (MRT) and
half life (t1/2) were statistically higher (P<0.05) for PEG-LtEc as compared to LtEc. Addition-
ally, the terminal K (terminal slope) and clearance were found to be statistically lower
(P<0.05) after PEGylation. The maximum plasma concentration (Cmax) and volume of distri-
bution at steady state (Vss) were found to be statistically higher (P<0.05) after PEGylation.
Overall, PEG-LtEc has an improved circulatory persistence, found to be 4 times greater than
that of LtEc.
The concentration of the reduced (Fe2+) and oxidized (Fe3+) forms of PEG-LtEc and LtEc
as a function of time after exchange transfusion are displayed in Fig 2. The reduced PEG-LtEc
concentration was found to be statistically different (P<0.05) compared to the reduced LtEc
after 24 hours of circulation time, while oxidized PEG-LtEc was found to be statistically differ-
ent (P<0.05) compared to oxidized LtEc only after 1 hour of circulation time. The formation
of oxidized Fe3+ LtEc (i.e. metHb) was found to be statistically different (P<0.05) between
PEG-LtEc and LtEc after 1 hour of circulation time, while formation of reduced metHb was
found to be statistically different (P<0.05) between PEG-LtEc and LtEc after 12 hours of circu-
lation time. The functional fraction to transport and deliver O2 to tissue was overall reduced
by PEGylation of LtEc. However, the optimal increases in O2 carrying capacity requires both a
long circulation time coupled with functional half-life. Thus, the half-life of reduced forms of
PEG-LtEc and LtEc, is the appropriate parameter to compare improvements in O2 transport.
This study observed that 54 ± 5% of the administered PEG-LtEc remained functional to trans-
port O2 at 8 hours, while only 41 ± 6% of the administered LtEc remained functional to trans-
port O2 at 8 hours.
Pharmacodynamics of PEG- LtEc and LtEc
MAP and HR after infusion of PEG-LtEc and LtEc are presented in Fig 3. No statistical differ-
ences were observed for both MAP and HR between LtEc and PEG-LtEc.
Hematological and Blood Gas Parameters
Hct and total Hb were found to be statistically lower (P<0.05) for PEG-LtEc compared to LtEc
at a plasma protein concentration of 1.5 g/dL. No statistical differences were observed at lower
plasma protein concentrations. These results are summarized in Table 3. Additionally, no sta-
tistical differences in arterial blood pH, arterial blood pO2, and arterial blood pCO2 were
observed after infusion of PEG-LtEc and LtEc at all plasma concentrations (Table 4).
Table 2. Pharmacokinetics of LtEc and PEG-LtEc.
LtEc PEG-LtEc
Terminal K, h-1 0.04 ± 0.02 0.01 ± 0.01†
Half life, h 18.0 ± 0.8 66.8 ± 1.8†
CL, mL.h-1 3.82 ± 0.08 0.84 ± 0.06†
MRT, h 23.4 ± 0.9 95.7 ± 1.9†
Cmax, mg.h-1 2.85 ± 0.2 3.12 ± 0.22
Vss, mL 23.5 ± 1.1 80.6 ± 2.4†
Terminal K, terminal slope; CL, plasma clearance; MRT, mean residence timel; Cmax, concentration
maximal; Vss, volume of distribution at steady state.
†, P<0.05 compared to LtEc
doi:10.1371/journal.pone.0170041.t002
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Microvascular Hemodynamics
Blood vessel diameter and blood flow were measured for arterioles and venules with diameters
between 20 and 80 μm.
20–40 μm Arterioles. Changes in 20–40 μm arterioles diameter at various Hb concentra-
tions are shown in Fig 4. A statistically significant decrease in blood vessel diameter and
increase blood flow were observed from baseline blood vessel diameters at a plasma concentra-
tion of 1.5 g/dL and from baseline blood flow at all plasma concentrations greater than or
equal to 0.5 g/dL after infusion of LtEc. Infusion with PEG-LtEc, however, resulted in statisti-
cally significant decrease from baseline blood vessel diameters at all plasma concentrations
greater than or equal to 0.5 g/dL and statistically significant increase from baseline blood flow
at plasma concentrations less than 1.5 g/dL. No statistical differences were observed in blood
vessel diameters between the two groups; however, blood flow was found to be statistically
lower after infusion of PEG-LtEc compared to LtEc.
Fig 2. LtEc and PEG-LtEc pharmacokinetics after a 40% exchange transfusion (Top panels). The concentration of the reduced
(Fe2+) and oxidized (Fe3+) forms of PEG-LtEc and LtEc as a function of time (bottom panels).
doi:10.1371/journal.pone.0170041.g002
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Fig 3. Mean arterial pressure (MAP) and heart rate (HR) after hypervolemic infusion, of LtEc or PEG-LtEc. †, P < 0.05 relative to baseline; ‡,
P < 0.05 compared to LtEc. During the hypervolemic infusion, each animal was infused with enough material to increase its plasma protein concent-
ration to 0.5 g/dL, then given 30 minutes to recover. This process was repeated twice, ones to increase its protein concentration to 1.0 g/dL and then to
1.5 g/dL.
doi:10.1371/journal.pone.0170041.g003




Hct (%) 49 ± 1 49 ± 1
Hb (g/dL) 15.5 ± 0.4 15.7 ± 0.6
Body weight (g) 60.8 ± 2.0 61.9 ± 4.4
0.5 g/dL
Volume infused (mL) 0.096 ± 0.003 0.100 ± 0.006
Hct (%) 47 ± 1 46 ± 1
Hbtotal (g/dL) 14.6 ± 0.5 14.6 ± 0.4
Proteinplasma (g/dL) 0.5 ± 0.1 0.5 ± 0.1
Volume Expansion % 4 ± 2 6 ± 3
1.0 g/dL
Volume infused (mL) 0.198 ± 0.005 0.205 ± 0.959
Hct (%) 44 ± 1 43 ± 1
Hbtotal (g/dL) 13.8 ± 0.5 13.5 ± 0.7
Proteinplasma (g/dL) 1.1 ± 0.2 1.0 ± 0.1
Volume Expansion % 8 ± 1 7 ± 4
1.5 g/dL
Volume infused (mL) 0.302±0.005 0.315 ± 0.961
Hct (%) 43 ± 1 41 ± 1†
Hbtotal (g/dL) 13.2 ± 0.3 12.5 ± 0.3†
Proteinplasma (g/dL) 1.5 ± 0.1 1.5 ± 0.1
Volume Expansion % 3 ± 1 5 ± 3
†
, P<0.05 compared to LtEc
doi:10.1371/journal.pone.0170041.t003
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20–40 μm Venules. Changes in 20–40 μm venules diameter at various Hb concentrations
are shown in Fig 4. Statistically significant decrease in blood vessel diameter from baseline
were observed at plasma concentrations greater than 0.5 g/dL, while statistically significant
increases in blood flow from baseline were observed at all plasma concentrations greater than
or equal to 0.5 g/dL after infusion with LtEc. Furthermore, statistically significant decreases in
blood vessel diameter and increases blood flow from baseline were observed at a plasma con-
centration of 0.5 g/dL and at all plasma concentrations greater than or equal to 0.5 g/dL after
infusion with PEG-LtEc. Statistical differences in blood vessel diameter and blood flow were
observed between the two groups at plasma concentrations greater than 0.5 g/dL and at those
greater than 1.0 g/dL, respectively.
40–60 μm Arterioles. Changes in 40–60 μm arterioles diameter at various Hb concentra-
tions are shown in Fig 4. Statistically significant decreases in blood vessel diameter from base-
line were observed at all plasma concentrations greater than or equal to 0.5 g/dL while
statistically significant increases were also observed in blood flow from baseline at plasma con-
centrations greater than 1.0 g/dL after infusion with LtEc. However, PEGylation resulted in
statistically significant changes (increase at 0.5 g/dL and decrease at 1.5 g/dL plasma concen-
trations) in blood vessel diameter relative to baseline and in blood flow relative to baseline at
all plasma concentrations. Furthermore, statistically significant differences in blood vessel
diameter were observed between both groups at all plasma concentrations, while statistically
significant differences in blood flow between both groups were only observed at plasma con-
centrations of 0.5 and 1.0 g/dL.
40–60 μm Venules. Changes in 40–60 μm venules diameter at various Hb concentrations
are shown in Fig 5. After infusion of LtEc, statistically significant decreases in blood vessel
diameter from baseline were observed at plasma concentrations greater than 0.5 g/dL, while
statistically significant increases in blood flow from baseline were observed at plasma concen-
trations of 0.5 and 1.5 g/dL. However, statistically significant increases in blood vessel diameter
from baseline were observed at plasma concentrations greater than 0.5 g/dL and in blood flow
from baseline were observed at all LtEc plasma concentrations. Furthermore, statistically




pH 7.351 ± 0.015 7.355 ± 0.009
pO2, mmHg 72.8 ± 4.1 73.3 ± 4.1
pCO2, mmHg 46.3 ± 3.1 44.5 ± 2.3
0.5 g/dL
pH 7.349 ± 0.018 7.345 ± 0.023
pO2, mmHg 74.1 ± 3.9 73.1 ± 3.7
pCO2, mmHg 43.6 ± 3.7 43.5 ± 1.4
1.0 g/dL
pH 7.342 ± 0.022 7.342 ± 0.011
pO2, mmHg 76.8 ± 3.6 75.7 ± 3.7
pCO2, mmHg 43.4 ± 5.2 42.6 ± 2.0
1.5 g/dL
pH 7.340 ± 0.021 7.343 ± 0.013
pO2, mmHg 77.2 ± 5.4 76.5 ± 2.4
pCO2, mmHg 43.1 ± 4.3 42.5 ± 1.9
doi:10.1371/journal.pone.0170041.t004
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significant differences in blood vessel diameters were observed between groups at plasma con-
centrations greater than 0.5 g/dL, while statistically significant differences in blood flow were
observed between both groups at all plasma concentrations.
60–80 μm Arterioles. Changes in 60–80 μm arterioles diameter at various Hb concentra-
tions are shown in Fig 6. Infusion of LtEc resulted in statistically significant decrease in blood
vessel diameter from baseline and increase in blood flow from baseline at plasma concentra-
tions greater than 0.5 g/dL and at plasma concentrations of 0.5 and 1.5 g/dL, respectively.
However, infusion only resulted in statistically significant decreases in blood vessel diameter
from baseline at a plasma concentration of 1.0 g/dL, and statistically significant increases in
blood flow from baseline at plasma concentrations of 0.5 and 1.5 g/dL. Statistically significant
differences in blood vessel diameter between groups were observed at a plasma concentration
of 1.5 g/dL, while statistically significant differences in blood flow between groups were
observed at plasma concentrations of 0.5 and 1.5 g/dL.
60–80 μm Venules. Changes in 60–80 μm venules diameter at various Hb concentrations
are shown in Fig 6. After infusion of LtEc, statistically significant decrease in blood vessel
diameter from baseline and increase in blood flow from baseline were observed at plasma con-
centrations of greater than 0.5 g/dL and at plasma concentrations of 0.5 and 1.5 g/dL.
Fig 4. Changes in diameter and blood flow after hypervolemic infusion, of LtEc or PEG-LtEc, for small
arterioles and venules with diameters at baseline between 20–40 μm. †, P < 0.05 relative to baseline; ‡, P < 0.05
compared to LtEc. Vessel diameter and blood flow were studied at plasma protein concentration to 0.5, 1.0, and 1.5 g/
dL.
doi:10.1371/journal.pone.0170041.g004
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However, infusion of the PEGylated protein resulted in statistically significant increase in both
blood vessel diameter and blood flow from baseline at all plasma concentrations (0.5, 1.0, and
1.5 g/dL), and at plasma concentrations less than 1.5 g/dL, respectively. Furthermore, statisti-
cally significant differences in blood vessel diameter and blood flow were observed between
both groups at all plasma concentrations (0.5, 1.0, and 1.5 g/dL).
Functional Capillary Density
FCD after infusion of PEG-LtEc and LtEc is presented in Fig 7. Statistically significant changes
in FCD were observed at plasma concentrations less than 1.5 g/dL after infusion with LtEc,
while no statistically significant differences in FCD were observed after infusion with PEG-L-
tEc. Furthermore, no statistically significant differences in FCD were observed between groups
at all plasma concentrations.
Discussion
The principal results obtained in this study confirm LtEc’s potential as an O2 carrying thera-
peutic. PEGylation of LtEc significantly extended LtEc circulation half-life to 66.8 ± 1.6 hours,
which was 3.6 times longer than unPEGgylated LtEc. However, PEGylation increased the rate
of oxidation of LtEc in vivo. As early as 12 hours after infusion, PEG-LtEc is 35% oxidized to
metHb, whereas LtEc is only 16% oxidized to metHb. Infusion of PEG-LtEc caused a
Fig 5. Changes in diameter and blood flow after hypervolemic infusion, of LtEc or PEG-LtEc, for small
arterioles and venules with diameters at baseline between 40–60 μm. †, P < 0.05 relative to baseline; ‡,
P < 0.05 compared to LtEc. Vessel diameter and blood flow were studied at plasma protein concentration to
0.5, 1.0, and 1.5 g/dL.
doi:10.1371/journal.pone.0170041.g005
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statistically significant increase in both arteriolar and venular diameters and blood flow rela-
tive to baseline. However, no physiologically relevant hemodynamic alterations were observed
after infusion of PEG-LtEc systemically or in the microvasculature. In addition, PEG-LtEc pre-
served MAP, HR, and FCD relative to baseline, and with minor variations from baseline com-
pared to LtEc. No sign of systemic hypertension was observed after infusion of PEG-LtEc.
Additionally, no statistically significant differences were observed in volume expansion after
infusion between groups infused with PEG-LtEc and those with LtEc. Volumes required to
similar increases in plasma concentration were also not statistically difference between both
the PEG-LtEc and LtEc groups. Minor increases in COP after PEGylation of LtEc likely did
not exert a significant physiological effect due to the already large molecular size of LtEc. Low
COP of both LtEc and PEG-LtEc is advantageous over smaller diameter HBOCs. For example,
PEGylation of human Hb (PEG-Hb) increases solution COP, leading to volume expansion
post infusion, as fluid from the interstitial space moves into the vascular space, reducing the
PEG-Hb plasma concentration (i.e. facilitating autotransfusion) and consequently reducing
PEG-Hb O2 carrying capacity via hemodilution.[26] In addition, all the animals used in this
study showed no allergic reactions to PEG-LtEc or LtEc, which confirms that ultra-purification
of LtEc eliminates all harmful substances.[14, 15, 18]
Mass spectrum of the purified LtEc confirmed presence of all the LtEc subunits and linkers
proteins near their expected MWs; while the mass spectrum of the PEG-LtEc confirms
that only a fraction of the LtEc subunits were modified by one or two PEG chains during
Fig 6. Changes in diameter and blood flow after hypervolemic infusion, of LtEc or PEG-LtEc, for small
arterioles and venules with diameters at baseline between 60–80 μm. †, P < 0.05 relative to baseline; ‡,
P < 0.05 compared to LtEc. Vessel diameter and blood flow were studied at plasma protein concentration to
0.5, 1.0, and 1.5 g/dL.
doi:10.1371/journal.pone.0170041.g006
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PEGylation. The non site-specific PEGylation protocol used to generate PEG-LtEc, resulted in
a limited homogeneity in the location of the PEG chains. Steric hindrance due to the large size
of PEG chains is responsible for limited PEGylation as accessibility by the PEG chains to the
subunit was limited. PEGylation using extension arm based on thiol-maleimide chemistry
could allow for increasing the number of PEG chains attached to the protein [27]. However,
increasing the number of PEG chains on the protein surface still restricts the space available
on the protein surface. Consequently, the additional PEG-chains are projected into the solvent
phase and are not covering the protein. Mass analysis of LtEc and PEG-ltEc did not detected
notable impurities. PEG-LtEc represents a promising technology to increase O2 transport
when blood is not available for transfusion. Although, the development of PEG-LtEc as a viable
alternative to allogenic blood poses many new questions, including efficacy, safety, and clear-
ance. The basis of HBOC toxicity has been poorly understood, since industry research has not
been shared among investigators. This study reveals that LtEc is cleared more rapidly from the
vascular compartment compared to the PEG-LtEc, which implies that the LtEc degradation
begins immediately upon administration. Pilot studies radiolabeling LtEc illustrated no signifi-
cant accumulation in tissues after 48 hours (data no shown). However, future research explor-
ing the exact mechanism for the removal of the LtEc and PEG-LtEc need to be performed.
Small arterioles are the most sensitive to HBOCs vasoactivity and thus are the active regula-
tors of blood flow. In the analysis of the effects of LtEc and PEG-LtEc on vasoactivity, it is nec-
essary to consider both the type of vessel and size, as the capacity of microvessels to change
Fig 7. Changes in functional capillary density (FCD) relative to baseline after hypervolemic infusion, of LtEc or
PEG-LtEc. FCD was studied at plasma protein concentration to 0.5, 1.0, and 1.5 g/dL. FCD (capillaries per unit of area,
cm−1) at baseline for LtEc were 119 ± 14, and for PEG-LtEc were 116 ± 16, respectively. †, P < 0.05 relative to baseline;
‡, P < 0.05 compared to LtEc.
doi:10.1371/journal.pone.0170041.g007
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diameter is different depending on the baseline diameter. Arterioles of 60 to 80 micrometers
tend to be more responsive to vasoconstriction; however, when they constrict, the smaller arte-
rioles tend to increase their diameter, as result of myogenic regulation (pressure-induced vas-
cular control). The myogenic regulation is aimed to maintain constant the circumferential
stress (so called, hoop stress) resulting from the vascular transmural blood pressure. Therefore,
when the large arteriole constricts, the pressure downstream decreases and the diameter of
smaller arterioles downstream initially passively follows the reduction in pressure. However,
the subsequent myogenic response residing in the smooth muscle itself, relaxes the smooth
muscle causing the diameter to increase to normalize the circumferential stress. Therefore,
grouping a broad range of microvascular vessels will reduces the capacity to detect changes in
diameter in the microcirculation. This study assessed the differences vasoconstrictive response
to LtEc and PEG-LtEc at various vessels diameters. To the best of our knowledge, the lack of
vasoactivity of LtEc and PEG-LtEct at the various arteriolar and venular diameters, strongly
suggest an overall minimal vasoconstrictive response at intravascular concentrations of up to
1.5 g/dL. The changes in arteriole and venule diameter after infusion of PEG-LtEc were mostly
vasodilatory from baseline.
Much of the work directed at uncovering the mechanisms of vasoactivity of HBOCs has
been conducted using changes in blood pressure and/or systemic vascular resistance. Studies
studies, in which HBOCs are infused or used to restore blood volume after blood is removed
via hemorrhage, have significant limitations. Changes in blood pressure and/or systemic vas-
cular resistance are in part the result of changes in blood volume resulting from the adminis-
tration protocol used to infuse the HBOC. Our protocol to administer the LtEc and the PEG-
ltEc (exchange isovolemic transfusion) minimally disrupts blood volume, and allows for the
quantification of the volume expansion. Therefore, changes in blood pressure can be better
interpreted as part of the vasoactive responses or the result of volume expansion. PEG-LtEc
did not cause vasoconstriction or hypertension compared to small polymerized Hbs solutions.
[18] Instead, PEG-LtEc appeared to slightly relax small blood vessels. The high viscosity of
PEG-LtEc (1.9 cP) relative to plasma viscosity (1.2 cP), may also help to produce vasodilation,
as plasma viscosity increases endothelial wall shear stress on the blood vessel wall, which stim-
ulates endothelial cell production of vasodilators, including NO and prostacyclin.[28] Previous
studies have shown that high viscosity HBOCs improved microvascular function and main-
tained perivascular NO levels relative to low viscosity HBOCs.[28]
In contrast to most HBOCs, LtEc, even after PEGylation, is not vasoconstrictive. The most
accepted mechanism to account for HBOC-induced vasoconstriction is the scavenging of NO
through the NO dioxygenation that converts HbO2 to metHb and nitrate.[29] The close prox-
imity of circulating HBOCs to the endothelial lining (in contrast to the cell free zone that limits
access of RBCs to the endothelial wall) is considered a factor that limits the efficacy of HBOCs
with respect to NO scavenging. There are, however, HBOCs that do not induce vasoconstric-
tion.[30, 31] These HBOCs consist of high O2 affinity Hbs with large molecular diameters.
High O2 affinity HBOCs are usually the result of enhanced stabilization of the relaxed (R) qua-
ternary structure of Hb via chemical modification, which is significant as the rate at which
deoxyHb converts nitrite to NO is a function of the quaternary structure of Hb [32–37]. The
R-state quaternary conformation has much higher nitrite reductase activity relative to the T-
state quaternary conformation.[38, 39] The dependence of the nitrite reductase reaction on
the quaternary structure of Hb is at least in part due to the difference in the redox potential of
the two quaternary state conformations.[40, 41] The R-state conformation has a much lower
redox potential, which favors oxidation of a ferrous heme to a ferric heme, as is the case of the
nitrite reductase reaction. The intent of the nitrite reductase data presented in Fig 1B is to
demonstrate the difference in nitrite reactions between the HbA, LtEc and PEG-LtEc, and to
Red Blood Cell Substitute with Unique Biophysical Properties
PLOS ONE | DOI:10.1371/journal.pone.0170041 January 18, 2017 17 / 22
confirm that PEGylation of LtEc preserves the nitrite LtHb reaction, characteristics that can be
attributed to the different heme populations of LtEc [42]. The proposed basis for the absence
of vasoactivity is a compensatory mechanism in the form of the nitrite reductase reaction that
generates NO from nitrite.[10] Overall measured nitrite reductase rate for Peg-LtEc and LtEc
indicates a much slower rate as compared to that of HbA, which is consistent with their redox
potentials. The rates of autoreduction of the Fe3+NO derivatives from the nitrite reductase
reaction follow a similar pattern in the PEG-LtEc, and the LtEc is consistent with a functional
heterogeneity among the heme sites in LtHb. The functional heterogeneity of the LtEc heme
subunits allows LtEc to function both as a stable O2 transport protein and as an NO/nitrite-
detoxifying agent. This critically important dual functionality could be the result of the driving
force for the evolution of subunits with different redox properties. Alternatively, hydrody-
namic forces, similar to those that repel particles away from the vessel wall and create the cell-
depleted zone, may limit the accessibility of the LtEc protein complex to the endothelium due
to its large molecular size.
PEG-LtEc’s longer half-life can be attributed to the relatively hydrophobic polyether back-
bone, which facilitates extensive hydrophobic interaction, resulting in the formation of clath-
rate cages of H2O molecules around PEG-LtEc. Additionally, an immune response to
PEGylation is not observed primarily because the polyether backbone around LtEc present
after PEGylation results in steric hindrance, which in turn inhibits recognition of PEG-LtEc by
immune cells. [17, 32, 43] Hence, this mechanism slows the rate at which the immune system
clears the circulation of PEG-LtEc. Despite met-PEG-LtEc concentrations remaining increased
after exchange transfusion, PEG-LtEc concentrations continued to remain stable after 12
hours of circulation. However, this was still found to be lower than that of other HBOCs,
which undergo 40% oxidation to metHb in less than 12 hours circulation time. It is speculated
that covalent bonding of PEG on specific regions of LtEc have caused either a conformational
or electrostatic change that could alter the redox properties of the protein complex, hence
altering PEG-LtEc’s autoxidation rate. Furthermore, it was observed that PEG-LtEc appears to
have little or no immunogenic effect after consecutive infusions in plasma. As a result, PEG-L-
tEc appears to be safe, like LtEc, with the greater advantage of a substantially longer half-life.
The short circulation time of LtEc was similar to that observed in a previous study.[14, 18]
In addition, our study confirmed that the level of Fe3+ (met-LtEc) reached a maximum con-
centration of 17% in 10 hours, which was much lower than that of other HBOCs.[14] Overall,
systemic and microvascular hemodynamic results were consistent with previous studies, in
which animals were hemodiluted with LtEc to demonstrate its ability to transport and deliver
O2.[14] Additionally, previous studies have demonstrated that PEGylation of large proteins
decreased the rate of renal clearance and increased the proteins’ biocompatibility, solubility,
stability, as well as significantly increasing the circulation half-life.[43]. The long circulatory
half-life of PEG-LtEc can be attributed to the hydrophobic polyether backbone, which entropi-
cally favors the formation of clathrate cages of water molecules on the LtEc surface.[17, 32] As
a result, water cannot hydrogen bond with other nucleophiles present in the circulation, thus
increasing the probability of nucleophilic attack of the heme groups, which in turn accelerates
metHb formation, explaining the higher oxidation rate of PEG-LtEc relative to LtEc.[10, 32]
In addition, cooperativity was significantly reduced, with the Hill coefficient decreasing by
20% from 2.4 to 1.9 for LtEc and PEG-LtEc, respectively. The changes in O2-binding proper-
ties of LtEc upon PEGylation are like those observed for PEGylated human Hb, in which coop-
erativity decreases due enhanced stability of the Hb R quaternary state [35]. Considering the
stability of the LtEc, this effect is also likely due to the steric effects of the PEG moieties, which
prevent the transition between the T and R states, as reported for Hb.
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The findings of this study provide evidence to continue development of LtEc as HBOCs.
Annually, 15 million RBC units are transfused in the US, while 80 million RBC units are trans-
fused globally. Safe PEG-LtEc can be optimally used to avoid unnecessary transfusions that are
costly and increase the risk of transfusion related diseases and immune responses. LtEc can be
produced and made available easily at a low cost and large quantities to avoid blood shortages.
PEG-LtEc can be rapidly available for transfusion in scenario with limited resources, since
there is no need for grouping or typing pre-transfusion. Furthermore, LtEc has the potential to
reduce the transmission of yet to be identified pathogens post transfusion, since it is an ultra-
purified protein. Unlike previously developed HBOCs, there were no signs of vasoconstriction,
systemic hypertension, renal failure, nor allergic reactions in hamsters treated with PEG-LtEc.
Additionally, PEG-LtEc is a suitable HBOC for people with religious objections to blood trans-
fusion. In trauma situations, such as resuscitation from hemorrhagic shock, PET-LtEc transfu-
sion increases blood flow, increasing tissue perfusion in addition to just O2 carrying capacity.
In conclusion, this study confirms that: 1) LtEc is a potential O2 transporter in mammals,
2) intravascular administration of PEG-LtEc has no acute adverse side-effects, 3) PEG-LtEc
increases LtEc circulation time, and 4) PEG-LtEc does no elicit vasoconstriction or hyperten-
sion, but increases microvascular blood flow. The latter can enhance the benefit of PEG-LtEc’s
O2 carrying capacity by increasing O2 delivery via increased tissue perfusion. In addition,
PEG-LtEc’s longer circulation half-life compared to that of LtEc allows for less frequent
HBOC administration and extends the benefit of a single administration of PEG-LtEc, until
blood for transfusion is available. Additionally, PEG-LtEc can be purified and synthesized at a
reasonable cost and its production is scalable. PEG-LtEc’s unique structure and stability in
addition to its large molecular size and longer half-life renders it a potent molecule for the
development of the next generation of HBOCs. Future studies will be aim to evaluate the O2
carrying and delivery capacity of PEG-LtEc.
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